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Summary
. Data suitable for urea reduction ratio (URR) analyses
were available for 14,761 (71.9%) of the 20,539
patients receiving haemodialysis (HD) in the UK
on the 30/9/2014.
. In 2014, 88.6% of prevalent HD patients achieved a
URR .65%. The between centre range of prevalent
patients achieving this target was wide (74.9–
97.0%).
. The median URR in 2014 was 75%.
. URR was greater in those with longer dialysis
vintage, with 91.2% of patients who had survived
on renal replacement therapy (RRT) for more
than two years achieving a URR .65% compared
with only 73.4% of those on RRT for less than six
months.
. Large variation between centres in the percentage of
patients achieving the UK Renal Association’s (RA)
URR guideline persists.
Fax +41 61 306 12 34
E-Mail karger@karger.com
www.karger.com/nef
# 2016 The UK Renal Registry
Published by S. Karger AG, Basel
1660–8151/16/1325–0155$39.50/0
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense).
Usage and distribution for commercial purposes as well as any
distribution of modified material requires written permission.
Andrerw Davenport
UK Renal Registry, Southmead Hospital, Southmead Road,
Bristol, BS10 5NB, UK
Email: renalregistry@renalregistry.nhs.uk
Nephron 2016;132(suppl1):155–168
DOI: 10.1159/000444821
Published online: April 19, 2016
D
ow
nl
oa
de
d 
by
: 
UC
L 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
12
8.
41
.6
1.
11
1 
- 2
/1
/2
01
7 
6:
12
:4
5 
PM
Introduction
The UK Renal Registry (UKRR) started collecting data
from dialysis centres in England, Wales and Northern
Ireland approximately 20 years ago. At that time haemo-
dialysis facilities were limited, and one of the objectives of
the UKRR, in collaboration with the UK Renal Associ-
ation was to provide data on haemodialysis provision,
and quality metrics compared to clinical standards set
by the Renal Association [1], designed to establish parity
between centres and improve provision and delivery of
treatments.
The traditional paradigm for determining haemo-
dialysis adequacy is based on sessional urea clearance,
and both prospective and observational studies have
reported an association between urea clearance and patient
outcomes [2, 3]. The delivered dose of HD depends on
both treatment factors (duration and frequency of dialysis
sessions, dialyser size and characteristics, dialysate and
blood ﬂow rate) and patient characteristics (including
size, protein intake, physical activity, haematocrit and vas-
cular access) [4]. The most widely accepted measures of
urea clearance are Kt/V, the ratio between the product of
urea clearance (K, in ml/min) and dialysis session duration
(t, in minutes) divided by the volume of distribution of
urea in the body (V, in ml) and urea reduction ratio,
which is derived solely from the percentage fall in serum
urea during a dialysis treatment. Whilst Kt/V is a more
accurate descriptor of urea clearance, its calculation is
more complex and requires additional data items not
commonly reported by most UK renal centres [5–7].
The UKRR has historically presented analyses based on
URR rather than Kt/V for comparative audit of haemo-
dialysis adequacy as these data are more widely available.
On one hand, URR does not take into account the
rebound in serum urea concentration at the end of
dialysis, and so may over estimate delivered dialysis
dose, particularly when higher blood pump speeds are
used, whereas on the other hand URR does not include
any estimate of residual renal function (RRF).
Clinical practice guidelines have been developed by
various national and regional organisations [1, 8, 9],
with considerable uniformity to the minimum dose of
dialysis recommended, although there are differences in
the methodology advised. Table 7.1 outlines the recom-
mended UK RA audit measures for haemodialysis
patients and whether the audit measure is currently
reported in the annual UKRR report [1].
The objective of this chapter is to determine haemo-
dialysis practice patterns in the UK, and the extent to
which patients undergoing HD treatment received the
dose of HD, as measured by URR, recommended by
the current UK RA clinical practice guidelines [1].
Methods
Seventy-one renal centres in the UK submitted data electroni-
cally to the UKRR on a quarterly basis. The majority of these
centres have satellite units but for the purposes of this study the
data from the renal centres and their associated satellite units
were amalgamated. Data from two groups of patients were
Table 7.1 Summary of recommended Renal Association audit measures relevant to haemodialysis adequacy [1]
RA audit measure
Included in UKRR
annual report? Reason for non-inclusion
Haemodialysis adequacy audit measures
Audit measure: The proportion of patients in the main renal centre and
its satellite units who are on twice weekly haemodialysis
No Varying levels of reporting
between centres
Audit measure: Cumulative frequency curves of urea reduction ratio
measured using a standard method of post-dialysis sampling
Yes, but data not
presented in the
cumulative frequency
format
Audit measure: The proportion of patient non-attendances for
haemodialysis sessions and the proportion of dialysis sessions shortened at
the patient’s request
No Data not available
Audit measure: The proportion of thrice weekly haemodialysis sessions
which have prescribed treatment times less than 4 hours
No Varying levels of reporting
between centres
Audit measure: The proportion of hospital (main and satellite unit) and
home haemodialysis patients who are prescribed more frequent than thrice
weekly haemodialysis
Yes Not for home
haemodialysis patients
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analysed. Firstly, analysis was undertaken using data from the
prevalent adult HD patient population as of the 30th September
2014. For this analysis, data for URR were taken from the 3rd
quarter of 2014 unless that data point was missing in which case
data from the 2nd quarter were taken. The prevalent population
only included patients receiving HD who were alive on September
30th 2014. Data from those patients who had died before that date
have not been included in the analysis. The second analysis
involved adult incident patients who had commenced treatment
with HD during 2013. For these patients, analysis was undertaken
using the last recorded URR in the quarter in which the patient
had started dialysis. The incident HD patient cohort was followed
up for one year and the last recorded URR in the quarter after one
year follow-up was used for this analysis.
Data from patients known to be receiving more or less than
thrice weekly HD were omitted from the analysis for both the
incident and prevalent population. Patients for whom data record-
ing the number of dialysis sessions per week were missing, were
assumed to be dialysing thrice weekly. However, because not all
centres report frequency of HD, it is possible that data from a
small number of patients receiving HD at a different frequency
were included in the analyses. Home HD patients were excluded
from the analysis.
Analyses of the data from both groups of patients included the
calculation of the median URR and of the proportion of patients
who had achieved the RA guideline (as outlined below) in each
of the renal centres as well as for the country as a whole. The
median URR and proportion of patients who achieved the RA
guideline were also calculated separately for males and females.
The number of dialysis sessions per week and the time per dialysis
session is shown by renal centre.
All patients with data were included in the statistical analyses at
a national level, although centres with fewer than 20 patients, or
providing less than 50% data completeness were excluded from
the comparison between centres. The number preceding the centre
name in each ﬁgure indicates the percentage of missing data for
that centre.
The UK RA clinical practice guidelines in operation at the time
these data were collected were as follows:
HD should take place at least three times per week in nearly
all patients. Reduction of dialysis frequency to twice per week
because of insufﬁcient dialysis facilities is unacceptable.
Every patient receiving thrice weekly HD should have
consistently:
. either URR >65%
. or equilibrated Kt/V (eKt/V) of >1.2 (or single pool Kt/V of
>1.3) calculated from pre- and post-dialysis urea values,
duration of dialysis and weight loss during dialysis).
To achieve a URR above 65% or eKt/V above 1.2 consist-
ently in the vast majority of the HD population clinicians
should aim for a minimum target URR of 70% or minimum
eKt/V of 1.4 in individual patients.
The duration of thrice weekly HD in adult patients with
minimal residual renal function should not be reduced
below 4 hours without careful consideration.
Patients receiving HD twice weekly for reasons of geogra-
phy should receive a higher sessional dose of HD. If this
cannot be achieved, then it should be recognised that there
is a compromise between the practicalities of HD and the
patient’s long-term health.
Measurement of the ‘dose’ or ‘adequacy’ of HD should be
performed monthly in all hospital HD patients and may be
performed less frequently in home HD patients. All dialysis
units should collect and report this data to their regional
network and the UKRR.
Post-dialysis blood samples should be collected either by
the slow-ﬂow method, the simpliﬁed stop-ﬂow method, or
the stop dialysate ﬂow method. The method used should
remain consistent within renal units and should be reported
to the Registry.
The RA clinical practice guidelines for HD dose apply speci-
ﬁcally to patients undergoing thrice weekly HD. In these patients
it is recommended that blood for biochemical measurement
(including pre-dialysis urea for URR) should be taken before the
mid-week dialysis session [1].
Results
Data completeness
Sixty four of the 71 renal centres submitted HD dose
(URR) data to the UKRR (table 7.2). Data were available
for 71.9% (N = 14,761) of the total prevalent population
(N = 20,539) treated with HD who met the inclusion
criteria for these analyses.
Fifty centres reported URR data on more than 90% of
patients. Thirteen centres reported URR data on less than
50% of prevalent patients (Carshalton, Manchester RI,
Newcastle, Reading, Brighton, Sunderland), with no
URR data received from seven centres (London Barts,
London King’s, London Royal Free, London St Georges,
Liverpool Aintree, Liverpool Royal Inﬁrmary, Wirral).
Several centres had a reduction in the completeness of
URR data submitted to the UKRR in 2014 compared with
2013 (data not shown). These changes may represent
changes in data extraction, or a move by centres to utilis-
ing Kt/V rather than URR as the preferred measure of
dialysis dose.
Of the total incident patient population (N = 4,404)
who started HD during 2013 and meeting the inclusion
criteria for URR analyses, 48.5% (N = 2,137) had URR
data available during the ﬁrst quarter of treatment (data
not shown).
Data completeness on the number of HD sessions per
week varied between centres (table 7.3). Seven centres in
England and four centres in Wales returned no data. All
centres in Northern Ireland returned data for 100% of
their HD population. All centres in Scotland returned
data in over 95% of their HD population.
UK haemodialysis dose Nephron 2016;132(suppl1):155–168 157
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For those centres returning data, three dialysis sessions a
week was most prevalent, although a few centres reported
.10% of HD patients receiving more or less than thrice
weekly treatments (table 7.3). For example, Salford
reported 20.1% of patients receiving more than three
sessions a week, whereas Southend reported 14.0% of
patients having less than three sessions per week.
Again there was a wide variation between centres in
completeness of data on dialysis session time (table 7.4).
The great majority of prevalent patients dialysed between
3.5–5.0 hours, although there was variation. Taking centres
with 99% or greater data completion for time per dialysis
session, then London King’s reported 16.3% of patients
dialysing ,3.5 hours per session, and Newcastle reported
dialysing 1.3% of patients for more than ﬁve hours per
session.
Achieved URR
TheUKmedianURR reported for prevalentHDpatients
was 75.0% (centre range 71.0–82.5%) (ﬁgure 7.1a), with a
Table 7.2. Percentage completeness of URR data returns for prevalent patients on HD by centre, on 30/9/2014
Centre N % completeness Centre N % completeness
England
B Heart 347 100.0 Sheff 487 96.7
B QEH 841 96.1 Shrew 142 97.9
Basldn 146 95.9 Stevng 389 99.7
Bradfd 179 100.0 Sthend 98 99.0
Brightn 347 4.3 Stoke 256 75.0
Bristol 443 100.0 Sund 173 0.6
Camb 265 96.2 Truro 118 82.2
Carlis 62 98.4 Wirral 169 0.0
Carsh 688 0.7 Wolve 276 90.9
Chelms 102 94.1 York 103 100.0
Colchr 109 91.7
Covnt 323 99.1 N Ireland
Derby 191 92.7 Antrim 113 97.4
Donc 159 99.4 Belfast 161 98.8
Dorset 248 100.0 Newry 82 84.2
Dudley 145 97.9 Ulster 88 98.9
Exeter 352 99.7 West NI 87 95.4
Glouc 206 100.0
Hull 298 99.3 Scotland
Ipswi 104 100.0 Abrdn 185 99.5
Kent 360 98.3 Airdrie 171 98.8
L Barts 889 0.0 D & Gall 29 96.6
L Guys 556 63.9 Dundee 150 100.0
L Kings 480 0.0 Edinb 250 100.0
L Rfree 650 0.0 Glasgw 529 99.6
L St.G 270 0.0 Inverns 53 100.0
L West 1,309 88.2 Klmarnk 123 100.0
Leeds 423 99.8 Krkcldy 135 99.3
Leic 790 99.5
Liv Ain 131 0.0 Wales
Liv Roy 257 0.0 Bangor 65 100.0
M RI 418 3.8 Cardff 416 99.0
Middlbr 302 99.3 Clwyd 73 97.3
Newc 233 13.7 Swanse 283 71.4
Norwch 275 98.2 Wrexm 101 100.0
Nottm 306 92.8
Oxford 387 98.2 England 17,445 67.6
Plymth 128 93.8 N Ireland 531 95.7
Ports 499 95.6 Scotland 1,625 99.6
Prestn 475 77.9 Wales 938 90.7
Redng 256 9.8 UK 20,539 71.9
Salford 285 87.0
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Table 7.3. Number of dialysis sessions for prevalent patients on HD by centre, on 30/9/2014
Percentage
Percentage
Centre N completeness ,3 sessions 3 sessions .3 sessions
England
B Heart 381 83.7 8.8 89.3 1.9
B QEH 841 0.0
Basldn 152 98.7 0.0 96.0 4.0
Bradfd 192 100.0 5.7 93.2 1.0
Brightn 348 99.7 0.0 99.7 0.3
Bristol 471 100.0 4.0 94.1 1.9
Camb 298 98.7 9.2 88.8 2.0
Carlis 65 96.9 4.8 95.2 0.0
Carsh 693 99.3 0.4 99.3 0.3
Chelms 115 99.1 9.6 88.6 1.8
Colchr 109 100.0 0.0 100.0 0.0
Covnt 323 2.5
Derby 191 61.8 0.0 100.0 0.0
Donc 160 95.6 0.7 99.3 0.0
Dorset 252 99.2 1.2 98.4 0.4
Dudley 148 99.3 1.4 98.0 0.7
Exeter 375 99.7 4.5 93.9 1.6
Glouc 206 0.0
Hull 298 1.0
Ipswi 110 76.4 6.0 92.9 1.2
Kent 378 99.2 3.2 95.2 1.6
L Barts 889 0.0
L Guys 556 0.0
L Kings 480 100.0 0.0 100.0 0.0
L Rfree 650 0.0
L St.G 272 90.1 0.8 99.2 0.0
L West 1,320 41.4
Leeds 449 98.9 5.9 94.1 0.0
Leic 797 98.5 0.9 99.1 0.0
Liv Ain 141 99.3 2.1 92.9 5.0
Liv Roy 295 98.3 0.7 86.9 12.4
M RI 421 23.5
Middlbr 304 19.1
Newc 237 100.0 0.4 98.3 1.3
Norwch 281 99.6 1.4 97.9 0.7
Nottm 310 99.0 1.3 98.7 0.0
Oxford 387 100.0 0.0 100.0 0.0
Plymth 128 0.0
Ports 541 98.5 6.0 92.1 1.9
Prestn 475 0.0
Redng 259 98.8 0.4 98.8 0.8
Salford 360 99.7 0.8 79.1 20.1
Sheff 510 99.8 4.5 95.5 0.0
Shrew 153 100.0 5.2 92.8 2.0
Stevng 421 99.3 5.5 92.3 2.2
Sthend 114 100.0 14.0 86.0 0.0
Stoke 267 99.6 0.8 95.9 3.4
Sund 190 96.8 0.0 90.8 9.2
Truro 130 90.0 7.7 89.7 2.6
Wirral 187 98.9 1.1 90.3 8.6
Wolve 276 7.6
York 112 97.3 0.9 91.7 7.3
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median URR for women of 78.0% (centre range 71.0–
87.0%) compared with a median for men of 74.0% (centre
range 69.0–81.0%) (ﬁgures 7.1b, 7.1c). The percentage of
patients achieving the UK RA guideline of a URR .65%
was 88.6% for the UK, with a centre range of 74.9–
97.0% (ﬁgure 7.2). There continued to be variation
between renal centres in the percentage of prevalent
patients with a URR of .65%, with 23 centres attaining
the UK RA clinical practice guideline for .90% of
patients and 34 centres reporting a URR of .65% in
75–90% of patients (ﬁgure 7.2). The percentage of preva-
lent male HD patients achieving the URR target was
86.5% for theUK, with a centre range of 64.7–96.2%, com-
pared to 92.0% for prevalent female HD patients, with a
centre range of 73.6–100%.
Changes in URR over time
The proportion of patients attaining the UK RA guide-
line (sessional URR .65%) increased from 70.7% to
88.6% from 2001–2014, whilst the median URR has
risen from 70.0% to 75.0% during the same time period
(ﬁgure 7.3). However, between 2011 and 2014, there
has been no substantial increase in median URR reported
by centres in the UK, or in the percentage of patients
achieving the UK RA target.
Variation of achieved URR with time on dialysis
The proportion of prevalent HD patients who attained
the UK RA clinical guideline for sessional URR was
greatest for those who had been on dialysis for the longest
time (ﬁgure 7.4). In 2014, 73.4% of those dialysed for less
than six months had a URR .65%, whilst 91.2% of
patients who had survived and continued on RRT for
more than two years had a URR within the guideline
target. In all strata of time on dialysis, there has been
an improvement in the proportion of patients receiving
the target dose between 2000–2011, thereafter there has
been no substantial increase.
Table 7.3. Continued
Percentage
Percentage
Centre N completeness ,3 sessions 3 sessions .3 sessions
N Ireland
Antrim 114 100.0 0.0 99.1 0.9
Belfast 168 100.0 0.6 95.8 3.6
Newry 86 100.0 4.7 95.3 0.0
Ulster 91 100.0 1.1 96.7 2.2
West NI 99 100.0 2.0 87.9 10.1
Scotland
Abrdn 196 100.0 1.5 94.4 4.1
Airdrie 171 97.1 0.0 100.0 0.0
D & Gall 41 100.0 4.9 70.7 24.4
Dundee 153 99.4 0.0 98.0 2.0
Edinb 251 99.6 0.4 99.6 0.0
Glasgw 533 95.5 0.6 99.2 0.2
Inverns 56 100.0 0.0 94.6 5.4
Klmarnk 123 98.4 0.0 100.0 0.0
Krkcldy 136 97.8 0.8 99.2 0.0
Wales
Bangor 65 0.0
Cardff 416 0.0
Clwyd 79 94.9 1.3 92.0 6.7
Swanse 283 0.0
Wrexm 101 0.0
England 18,018 65.4 2.7 95.1 2.1
N Ireland 558 100.0 1.4 95.2 3.4
Scotland 1,660 97.8 0.6 97.8 1.5
Wales 944 7.9
UK 21,180 66.3 2.4 95.4 2.2
Blank cells denote no data returned by that centre or data not shown due to ,50% data completeness
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Table 7.4. Time per dialysis session for prevalent patients on HD by centre, on 30/9/2014
Percentage
Percentage per dialysis session
Centre N completeness ,3.5 hours 3.5–5 hours 5+ hours
England
B Heart 347 76.7 4.5 95.1 0.4
B QEH 841 0.0
Basldn 146 98.6 11.8 88.2 0.0
Bradfd 179 99.4 8.4 91.6 0.0
Brightn 347 99.7 2.0 98.0 0.0
Bristol 443 100.0 5.6 94.4 0.0
Camb 265 0.0
Carlis 62 96.8 5.0 95.0 0.0
Carsh 688 97.7 1.8 98.2 0.0
Chelms 102 99.0 5.9 94.1 0.0
Colchr 109 100.0 0.0 100.0 0.0
Covnt 323 4.6
Derby 191 61.8 0.8 99.2 0.0
Donc 159 95.6 11.2 88.8 0.0
Dorset 248 99.2 2.8 97.2 0.0
Dudley 145 99.3 8.3 91.7 0.0
Exeter 352 100.0 19.0 81.0 0.0
Glouc 206 0.0
Hull 298 2.3
Ipswi 104 75.0 2.6 97.4 0.0
Kent 360 99.7 17.0 83.0 0.0
L Barts 889 0.0
L Guys 556 14.2
L Kings 480 100.0 16.3 83.8 0.0
L Rfree 650 0.0
L St.G 270 80.0 1.4 98.6 0.0
L West 1,309 41.3
Leeds 423 99.5 6.9 93.1 0.0
Leic 790 81.9 3.1 95.5 1.4
Liv Ain 131 100.0 14.5 85.5 0.0
Liv Roy 257 100.0 8.2 90.7 1.2
M RI 418 23.2
Middlbr 302 100.0 19.2 79.8 1.0
Newc 233 99.6 6.0 92.7 1.3
Norwch 275 99.6 16.1 83.9 0.0
Nottm 306 99.0 6.6 93.1 0.3
Oxford 387 100.0 8.3 91.5 0.3
Plymth 128 0.0
Ports 499 0.0
Prestn 475 0.4
Redng 256 94.1 0.8 99.2 0.0
Salford 285 94.4 6.3 93.3 0.4
Sheff 487 86.2 50.2 49.3 0.5
Shrew 142 100.0 12.7 87.3 0.0
Stevng 389 99.7 33.5 66.5 0.0
Sthend 98 100.0 26.5 73.5 0.0
Stoke 256 100.0 5.5 94.5 0.0
Sund 173 85.0 7.5 92.5 0.0
Truro 118 94.1 18.9 80.2 0.9
Wirral 169 100.0 17.8 81.7 0.6
Wolve 276 7.6
York 103 99.0 2.0 98.0 0.0
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Table 7.4. Continued
Percentage
Percentage per dialysis session
Centre N completeness ,3.5 hours 3.5–5 hours 5+ hours
N Ireland
Antrim 113 100.0 1.8 98.2 0.0
Belfast 161 100.0 9.3 90.7 0.0
Newry 82 100.0 9.8 90.2 0.0
Ulster 88 100.0 3.4 96.6 0.0
West NI 87 100.0 17.2 82.8 0.0
Scotland
Abrdn 185 98.9 1.1 97.3 1.6
Airdrie 171 95.3 5.5 93.9 0.6
D & Gall 29 82.8 0.0 95.8 4.2
Dundee 150 99.3 3.4 96.6 0.0
Edinb 250 99.2 9.3 89.9 0.8
Glasgw 529 94.9 1.6 93.8 4.6
Inverns 53 100.0 1.9 98.1 0.0
Klmarnk 123 90.2 0.0 100.0 0.0
Krkcldy 135 97.8 14.4 84.8 0.8
Wales
Bangor 65 0.0
Cardff 416 0.0
Clwyd 73 97.3 33.8 66.2 0.0
Swanse 283 0.0
Wrexm 101 0.0
England 17,445 60.3 10.6 89.1 0.3
N Ireland 531 100.0 8.1 91.9 0.0
Scotland 1,625 96.3 4.3 93.7 2.0
Wales 938 7.6
UK 20,539 61.8 9.9 89.6 0.5
Blank cells denote no data returned by that centre or data not shown due to ,50% data completeness
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Fig. 7.1a. Median URR achieved in prevalent patients on HD by centre, 30/9/2014
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Fig. 7.1b. Median URR achieved in female prevalent patients on HD by centre, 30/9/2014
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Fig. 7.1c. Median URR achieved in male prevalent patients on HD by centre, 30/9/2014
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Fig. 7.2. Percentage of prevalent patients on HD with URR .65% by centre, 30/9/2014
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The median URR during the ﬁrst quarter after initiat-
ing HD treatment of the incident HD population in
the UK in 2013 was 68% (centre range 58.0–77.5%)
(ﬁgure 7.5a). At the end of twelve months, the median
URR for this incident cohort was higher (median URR
74%, centre range 70–81%) (ﬁgure 7.5b).
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Fig. 7.5a. Median URR in the ﬁrst quarter of starting RRT in incident patients who started HD in 2013
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Conclusions
Although the dose of delivered HD is recognised as
having an important inﬂuence on outcome in HD
patients treated with low ﬂux HD, it remains unclear as
to whether higher urea clearance targets add beneﬁt [2,
10]. More recently, higher convective volume clearance
achieved with haemodiaﬁltration has been reported to
be associated with improved patient survival [11]. The
UKRR does not currently systematically collect data on
haemodialysis modality or dialyser ﬂux.
Since 2000, the proportion of UK patients achieving
the RA guideline for URR has steadily increased, with
more than 88% of the prevalent 2014 HD population
achieving the target, with a median URR of 75%. This
increase in delivered URR not only reﬂects improvements
in clinical practice and delivery of dialysis, but also
enhanced coverage and quality of the data collected by
the UKRR and renal centres over the years. However, it
must be acknowledged that not all centres contributed
data. This may be due to the difﬁculties in providing
pre and post treatment results, as with many centres
now dialysing in outlying satellites utilising evening and
overnight shifts, leading to difﬁculties in establishing
pre and post samples by registering different laboratory
dates. In addition pre and post urea data has to be cleaned
by excluding samples from HD patients admitted as
inpatients. Secondly, with the introduction of dialysis
machines with on-line clearance, some centres have
opted to record Kt/V data, which is not currently col-
lected by the UKRR.
Although the URR delivered has increased over time
there remained a wide range (74.9–97.0%) between dialysis
centres in the percentage of prevalent HD patients
achieving a URR of.65%. This is likely to reﬂect genuine
differences in the HD dose delivered consequent to both
individual patient and centre level factors, although
standardised methods for urea sampling are advised [1],
inconsistency in sampling methodology for the post-
dialysis urea sample may also play a part in the variations
reported. Understanding individual renal centre practice
would be informative, for example some centres may
determine residual renal function and adjust dialysis
sessions accordingly. Observational evidence supports
that preservation of residual renal function is associated
with improved survival [12], and reduced extracellular
water expansion [13], although there appears to be no
beneﬁt maintaining overhydration in patients to try and
preserve residual renal function [14]. Some centres may
be adopting an incremental approach to the imitation
of HD [15], starting patients on twice weekly dialysis
schedules or prescribing shorter dialysis sessions, as the
median URR for patients initiating dialysis was lower in
the ﬁrst quarter of starting dialysis, and then increased
over the course of the ﬁrst year of haemodialysis, but
remained lower than that of prevalent patients estab-
lished on dialysis, suggesting that dialysis treatments
were being adjusted according to residual renal function.
Although this may account for some of the differences in
dialysis frequency and session times, other centres are
known to favour higher blood ﬂows and shorter, but
more efﬁcient dialysis sessions. In the future the UKRR
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Fig. 7.5b. Median URR one year after starting RRT for incident patients who started HD in 2013
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will collect data from individual patient dialysis sessions,
which will allow closer inspection of centre practices.
The median URR was higher for women and more
women achieved the URR target in the UK than men.
This does not necessarily reﬂect a greater dose of HD
for women, and may simply reﬂect differences in dietary
intake and lower pre-dialysis serum urea values in
women [10, 16]. Paradoxically, although URR may be
higher for women, clearance of larger solutes may be
lower, as typically women have shorter session times
than men [10, 16].
The UK government changed reimbursement policy to
encourage the provision of more frequent dialysis sessions,
by switching to payment for each individual in-centre
treatment session [17]. However only four centres
reported providing510% of patients receiving more fre-
quent dialysis than thrice weekly, and ﬁve other centres
55%. This may reﬂect logistical problems in terms of
provision, although the option of more frequent dialysis
may also not have universal support from patients.
Although urea clearance is the paradigm for dialysis
adequacy, debate continues as to whether urea clearance
is representative of the clearance of azotaemic toxin [18,
19]. In addition to clearance of azotaemic toxins, the
dialysis prescription also encompasses volume control,
sodium and divalent cation balance and correction of
metabolic acidosis. As such, basing and evaluating HD
dose simply on urea clearance has been criticised, with
patient outcomes reported to be improved by longer ses-
sional times independent of urea removal [20] and that
clearance of ‘middle molecules’ may also have an impor-
tant effect [11, 21]. However, no consensus has yet
emerged on alternative markers of HD adequacy [18].
The UKRR has historically reported URR, predominantly
for logistical reasons with the URR being the simplest
measure of dialysis adequacy to calculate, and the
measure of dialysis adequacy that is most complete
when returned to the UKRR. However, limitations of
the URR must be recognised [22]. The revised UKRR
data set, due to be embedded in the 2016 dialysis centre
returns, should help contribute to further improvements
in both UK URR data capture, as well as Kt/V reporting
in addition to dialysis centre prescription practices.
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